Mr. Hugh MacNaught reports

VENTRIPOINT RECEIVES MEDICAL DEVICE LICENSE FROM HEALTH CANADA TO SELL NEXT GENERATION, AI-POWERED, HEART-SCANNING TECHNOLOGY

Ventripoint Diagnostics Ltd. has received a medical device licence from Health Canada for its latest product offering, VMS+4.0. This is a major milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to cardiac clinicians worldwide.

VMS+4.0 offers a significant improvement in user experience through the automation of the image processing steps. This streamlined workflow leads to a significant reduction in operator time without compromising the accuracy of the measurements. Additionally, this release is optimized to work seamlessly with Ventripoint's recently announced magnet-free sensors, further enhancing efficiency, ease of use and applicability.

"We are delighted to receive the licence and will immediately introduce the enhanced capabilities of the new version to Canadian cardiologists and health care providers," said Ventripoint president and chief executive officer Hugh MacNaught. "The advances introduced in VMS+4.0 enable its use for patients with intracardiac devices such as pacemakers and defibrillators, who cannot go into an MRI. This engineering breakthrough enlarges our market opportunity as it now empowers health care providers with a powerful tool that delivers accurate and reliable cardiac measurements in a more efficient manner and without the restrictions associated with MRI."

VMS+4.0 will be marketed as a premium product in Canada to complement the company's base product VMS+3.0, which has already received regulatory clearances from U.S.-FDA, Health Canada, the United Kingdom (U.K.) and the European Union (E.U.) and is being used by leading hospitals in the U.S., EU, U.K. and Canada.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

We seek Safe Harbor.